US biotech firm Medivation rejects Sanofi takeover bid
[NEW YORK] US biotech company Medivation rejected an unsolicited US$9.3 billion bid from French pharmaceuticals giant Sanofi Friday, saying the offer "substantially undervalues" the company.
Medivation, which makes the lucrative prostate cancer drug Xtandi, said it is poised to soon commercialise other promising cancer drugs in development. Staying independent will be far more lucrative for Medivation shareholders than accepting Sanofi's proposal, Medivation said.
"Over the past several years, we have established a world class oncology franchise and a unique, diversified and highly-promising late-stage development pipeline," said David Hung, founder and chief executive officer of Medivation.
"Sanofi's opportunistically-timed proposal, which comes during a period of significant market dislocation, and prior to several important near-term events for the company, is designed to seize for Sanofi value that rightly belongs to our stockholders." Sanofi disclosed its bid for Medivation on Thursday after being frustrated by a lack of response from the American drugsmaker two weeks after submitting an unsolicited offer.
AFP
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action